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Abstract
Background: Long QT syndrome (LQTS) is an inherited ion channel disorder manifesting with prolongation of the
cardiac repolarization phase and severe ventricular arrhythmias. The common KCNE1 D85N potassium channel
variant prolongs QT interval by inhibiting IKs (KCNQ1) and IKr (KCNH2) currents and is therefore a suitable candidate
for a modifier gene in LQTS.
Methods: We studied the effect of D85N on age-, sex-, and heart rate-adjusted QT-interval duration by linear
regression in LQTS patients carrying the Finnish founder mutations KCNQ1 G589D (n = 492), KCNQ1 IVS7-2A>G
(n = 66), KCNH2 L552S (n = 73), and KCNH2 R176W (n = 88). We also investigated the association between D85N
and clinical variables reflecting the severity of the disease.
Results: D85N was associated with a QT prolongation by 26 ms (SE 8.6, p = 0.003) in males with KCNQ1 G589D
(n = 213), but not in females with G589D (n = 279). In linear regression, the interaction between D85N genotype
and sex was significant (p = 0.028). Within the KCNQ1 G589D mutation group, KCNE1 D85N carriers were more
often probands of the family (p = 0.042) and were more likely to use beta blocker medication (p = 0.010) than
non-carriers. The number of D85N carriers in other founder mutation groups was too small to assess its effects.
Conclusions: We propose that KCNE1 D85N is a sex-specific QT-interval modifier in type 1 LQTS and may also
associate with increased severity of disease. Our data warrant additional studies on the role of KCNE1 D85N in
other genetically homogeneous groups of LQTS patients.
Background
Long QT syndrome (LQTS) is an inherited arrhythmia
disorder associated with risk of torsades de pointes, ven-
tricular fibrillation, and sudden death. LQTS is caused
by mutations of the ion channel genes controlling the
repolarization phase of the cardiac action potential cycle
[1,2]. The potassium channel KCNE1, also known as
minK, regulates both the voltage-gated slowly activating
IKs potassium channel [3,4], encoded by the KCNQ1
gene, and the rapidly activating IKr potassium channel
[5], encoded by the KCNH2 gene. Mutations in KCNE1
underlie the LQT5 subtype of LQTS [6] and account for
approximately 3% of known LQTS mutations [7]. In
homozygous form, KCNE1 mutations may cause sensor-
ineural hearing loss in association with LQTS, or Jer-
vell-Lange-Nielsen syndrome [8].
A common variant D85N of KCNE1 was originally
detected by Tesson et al. [9]. This variant has subse-
quently been shown to slow IKs potassium channel,
when studied in Xenopus oocytes [10], and to exhibit
significant loss-of-function effects on both the KCNQ1-
and KCNH2-mediated potassium currents, as measured
in Chinese hamster ovarian cells [11]. In general popula-
tion, KCNE1 D85N has a minor allele frequency of
0.8-1.4% [11-13] and is associated with a significant pro-
longation of the electrocardiographic QT interval
[12-14]. Moreover, D85N has been detected in many
LQTS patients as a second variant in addition to a more
severe mutation [10,11], as well as in some individuals
with drug-induced LQTS [15].
These findings prompted us to study whether KCNE1
D85N would also modify the QT interval and/or the
clinical picture in patients with genetically homogeneous
forms of LQTS in which the variability caused by the
disease-causing mutation itself can be controlled for. To
this end, we took advantage of the unique situation in
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approximately 70% of the known spectrum of LQTS
genes [16] and where the prevalence of molecularly
defined LQTS appears to be the highest in the world
[17]. Our results indicate a sex-specific QT-prolonging
effect for D85N in KCNQ1 mutation carriers.
Methods
Patient cohort
The study sample consisted of all available (n = 712)
carriers of the Finnish LQTS founder mutations, includ-
ing 492 carriers of KCNQ1 G589D (5 of them also
carried KCNH2 R176W, 1 KCNH2 L552S, and 1 a non-
founder nonsense mutation KCNQ1 Y171X), 66 carriers
of KCNQ1 IVS7-2A>G (1 of them also carried KCNH2
R176W), 73 carriers of KCNH2 L552S (2 of them homo-
zygous), and 88 carriers of KCNH2 R176W. These four
founder mutations account for 70%, and KCNQ1 G589D
alone 50%, of all Finnish LQTS patients with an estab-
lished molecular diagnosis of LQTS [16]. The collective
prevalence of these four founder mutations in the gen-
eral Finnish population is as high as 0.4% [17].
Subjects taking any known QT-prolonging medication at
the moment of electrocardiogram (ECG) recording were
excluded from the study. QT intervals were measured
manually by a single cardiologist (H.S.) using the mean of
two consecutive QT intervals in lead II in standard 12-lead
ECG. Heart rate-corrected QT (QTc) was calculated using
the Bazett’s formula (QT/√RR). The study was performed
in accordance with the Declaration of Helsinki and written
informed consent was obtained from all participants. The
Ethics Review Committee of the Department of Medicine,
University of Helsinki, approved the study.
Molecular genetic analyses
KCNE1 253G>A (D85N, rs1805128) was genotyped in
DNA from venous blood samples using polymerase chain
reaction with primers 5’-GAGATTGGAGTGGTG-
GATGGA-3’ and 5’-CACCCCTTACAACAGCCAAAA-
3’ followed by Lwe I digestion (Fermentas, Ontario,
Canada) and agarose gel electrophoresis. Previously iden-
tified heterozygous and major and minor homozygous
samples served as controls in the assay.
Statistical analyses
Normality of continuous distributions was reviewed
visually. Non-normally distributed age was normalized by
Blom’s method. The effect of KCNE1 D85N on age-, sex-,
and heart rate (RR interval) -adjusted QT interval was stu-
died by linear regression analysis using 1-df additive
model (genotype coded as D85D = 0, D85N = 1, N85N =
2). Because gender differences were detected, an additional
model included also a multiplicative interaction term
between KCNE1 D85N genotype and sex. In KCNQ1
G589D carriers, association of D85N with proband/family
member status (information available for all 492 G589D
carriers), appearance of syncope (information available, n
= 488), use of beta blocker medication (information avail-
able, n = 347), and occurrence of pacemaker or implanta-
ble cardioverter-defibrillator (information available, n =
349) was studied by Fisher exact test. Statistical analyses
were performed with SPSS 17.0 (Statistical Package for
Social Sciences, SPSS Inc., Chicago, IL, USA). A p value <
0.05 was considered statistically significant.
Results
Effect of KCNE1 D85N on QT interval in LQTS founder
mutation carriers
Of the 712 LQTS founder mutation carriers, 689 had
the KCNE1 genotype D85D, 21 had the heterozygous
genotype D85N, and 2 were minor homozygotes
(N85N) (Table 1). The frequency of the N85 allele was
1.8%, which is slightly higher than the corresponding
frequency in the general Finnish population (1.4%) [12]
and in other reported populations (0.8-1.0%) [11,13]. Of
the 21 D85N heterozygotes, 15 had the KCNQ1 G589D
mutation, 2 had KCNH2 L552S, 3 had KCNH2 R176W,
Table 1 The clinical characteristics of the study sample
D85D major
homozygotes
D85N
heterozygotes
N85N minor
homozygotes
All subjects
n (%) 689 (96.8) 21 (2.9) 2 (0.3)
Age (years) 29.7 ± 20.0 28.7 ± 20.2 7.0 ± 4.2
Males (%) 280 (40.6) 8 (38.1) 2 (100)
QTc (ms) 458 ± 36.8 472 ± 35.2 468 ± 34.6
Founder mutation
status
KCNQ1 G589D
n 474
a 16
b 2
QTc 459 ± 36.2 479 ± 31.0 468 ± 34.6
KCNQ1 IVS7-2A>G
n6 6
b 00
QTc 465 ± 30.0 - -
KCNH2 L552S
n7 1
c 20
QTc 464 ± 48.3 490 ± 7.1 -
KCNH2 R176W
n8 4
d 4
e 0
QTc 445 ± 30.6 442 ± 46.5 -
The figures represent the mean ± SD. SD, standard deviation; QTc, heart rate-
corrected QT interval.
aFour subjects carrying also KCNH2 R176W, one KCNH2 L552S, and one KCNQ1
Y171X.
bOne subject carrying also KCNH2 R176W.
cIncludes two KCNH2 L552S homozygotes and one subject carrying also
KCNQ1 G589D.
dFour subjects carrying also KCNQ1 G589D and one KCNQ1 IVS7-2A>G.
eOne subject carrying also KCNQ1 G589D.
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and KCNH2 R176W mutations. None of the KCNQ1
IVS7-2A>G mutation carriers had the minor N85 allele.
The two N85N minor homozygotes (boys aged 4 and
10) were KCNQ1 G589D carriers and were siblings from
the same family. As a whole, the founder mutation car-
riers were derived from 126 LQTS families. The number
of KCNE1 D85N carriers in type 2 LQTS was too small
for statistical comparisons and therefore the analyses
were confined to KCNQ1 G589D carriers and the com-
bined group of founder mutation carriers.
Patients with KCNQ1 G589D (n = 492) was the lar-
gest group of founder mutation carriers. A QT-
prolonging effect of 26 ms (SE 8.6, p = 0.003) was
detected in males with G589D (n = 213), whereas
D85N did not prolong QT interval in females with
G589D (n = 279) (Table 2, Figure 1). In our cohort,
all male KCNQ1 G589D carriers with KCNE1 N85 (n
=8 )w e r eo fa g e≤16. To account for the possible
confounding effect of age, male G589D carriers ≤16
years were analyzed also as a separate group. Even in
this analysis, the effect of N85 allele on QT interval
remained essentially the same (+23 ms, SE 8.8, p =
0.010). The majority (9 out of 10) of the female
KCNQ1 G589D carriers with KCNE1 D85N were
adults ≥18 years (median age 34 years, range 0-59
years). In order to further study the gender specificity
of D85N, a multiplicative interaction term for D85N
genotype and sex was introduced into the linear
model. This interaction term received a significance
of p = 0.028, indicating that D85N indeed has a sex-
specific effect for QT interval in KCNQ1 G589D
carriers.
When all founder mutation carriers were considered
together, KCNE1 D85N was associated with a 13 ms (SE
6.0) prolongation of QT interval per each N85 minor
allele (p = 0.028, Table 2). A similar gender-specific ana-
lysis revealed that this association was confined to males
(Table 2).
Association of KCNE1 D85N with selected clinical variables
The clinical importance of the LQTS-modifying effect of
KCNE1 D85N was studied in the largest founder muta-
tion group of KCNQ1 G589D carriers. In these subjects,
the proband/family member status, occurrence of syn-
cope, use of beta blocker medication, and use of pace-
maker or implantable cardioverter-defibrillator were
compared between the D85N heterozygotes and non-
carriers (Figure 2). Of the 16 D85N heterozygotes, 5
(31%) were probands, compared to 58 (12%) of the 474
D85D homozygotes (p = 0.042). The proportion of sub-
jects using beta blocker medication was also higher in
D85N heterozygotes (81%) than in D85D homozygotes
(47%, p = 0.010). The median age at which the medica-
tion was started was 15 years (range 0-58 years) for the
D85N heterozygotes and 8 years (range 5-11 years)
for the N85N minor homozygotes. A similar but non-
significant trend for difference between non-carriers and
heterozygotes was observed in the occurrence of syn-
cope and use of pacemaker or implantable-cardioverter
defibrillator (Figure 2).
Discussion
The KCNE1 D85N variant has been shown to lead to a
substantial QT-interval prolongation in the general
population [12-14]. In fact, we are not aware of any
other gene variant showing a population-based fre-
quency of >1% and an equally large effect on QT inter-
val. In order to test the effect of this variant on cardiac
repolarization in patients with LQTS, we studied the
association of KCNE1 D85N to QT interval in a homo-
geneous group of Finnish LQTS founder mutation car-
riers. We found that the minor N85 allele significantly
prolongs age-, sex-, and heart rate-adjusted QT interval
in type 1 LQTS patients with the mutation G589D. An
interaction between D85N genotype and sex was
detected (p = 0.028), and a sex-specific analysis revealed
that the N85 allele prolongs QT interval by 26 ms in
males but not in females (Table 2). Our material is too
small to draw conclusions of the role of D85N in LQTS
type 2 caused by KCNH2 mutations.
In this study, we detected a gender difference in the
effect of KCNE1 D85N on QT interval in type 1 LQTS.
We reported previously that the occurrence of the N85
minor allele was associated with a 10 ms prolongation
of the QT interval in the general Finnish population
[12]. We carried out a retrospect analysis of our popula-
tion sample [12] and found that the effect of D85N on
QT interval was slightly larger in males (+11.3 ms) than
in females (+10.0 ms). Gender is known to influence
QT interval at the population level, with females in gen-
eral showing longer QT intervals than males [18], and
there are sex- and age-specific differences in risk of
arrhythmias in the different subtypes of LQTS [19,20]. It
Table 2 Effect of KCNE1 D85N on age-, sex-, and heart
rate-adjusted QT interval
Total
n
n with
D85N
Effect
(ms)
SE
(ms)
p
value
All founder mutation
carriers
712 23 +13.1 6.0 0.028
Males
a 290 10 +20.1 7.7 0.010
Females
a 422 13 +1.6 9.1 0.857
KCNQ1 G589D carriers 492 18 +16.9 6.3 0.007
Males
a 213 8 +25.7 8.6 0.003
Females
a 279 10 +0.7 9.2 0.935
SE, standard error.
aQT interval adjusted by age and heart rate.
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difference since the female carriers have >20 ms longer
QTc compared to the male carriers [21], a finding repli-
cated in the present study (Figure 1, D85D homozy-
gotes). KCNE1 D85N appears to invert this sex
difference. Interestingly, Friedlander et al. [22] found
that G38S, another polymorphism of KCNE1, was asso-
ciated with QT-interval variation in healthy males but
not in females.
Sex differences in cardiac repolarization appear to
result from both transcriptional and non-transcriptional
regulatory mechanisms. In female mice hearts, KCNE1
mRNA is more abundant compared to males [23]. Dif-
ferences in KCNE1 protein levels may therefore influ-
ence the sex-specific sensitivity to KCNE1 variants. Sex
hormones have also been reported to alter the gating
kinetics of cardiac ion channels and to modulate the
effects of channel blocking agents [24,25]. For example,
17b-oestradiol inhibits IKs [24] and IKr [25] channels
and enhances the effect of a KCNH2 blocker [25]. It is
therefore possible that KCNE1 D85N interferes with the
binding of sex-specific IKs channel regulators, but the
exact mechanisms underlying the sex difference
reported in the present study remain to be explored.
In previous studies, KCNE1 D85N has been found to
associate with congenital LQTS [10,11]. Compound car-
riers of two or more LQTS mutations have a longer heart
rate-corrected QT interval (QTc) and a more severe phe-
notype than carriers of only one mutation [10,26]. KCNE1
D85N has also been proposed to cause LQTS in the
absence of any documented mutation in known LQTS
genes, but the age at onset may be higher and QTc shorter
than in patients with a more severe LQTS mutation [11].
In vitro experiments indicate that KCNE1 N85 signifi-
cantly reduces both IKs and IKr currents, thus delaying
repolarization in mammalian cells [11]. This gene variant
a l s oc o n t r i b u t e st ol o s so fI Ks function together with a
KCNQ1 mutation in Xenopus oocytes [10]. In another
study of mammalian cells, however, D85N did not affect
IKs current when co-expressed with KCNQ1 [27].
In the present study, we found that the QT-prolonging
effect of KCNE1 D85N is substantially larger in males
with the LQTS mutation KCNQ1 G589D (26 ms) than in
the general population (10 ms). This result suggests that
KCNQ1 and KCNE1 mutations and variants may interact
with each other, at least in males, to produce an even
more pronounced QT-prolonging effect than when
occurring separately. This interaction could be caused by
the coassembly of the two proteins to form a functional
IKs channel. However, due to small number of subjects
with the KCNE1 N 8 5a l l e l ea n dL Q T 1m u t a t i o n so t h e r
than KCNQ1 G589D, we cannot draw conclusions on the
general applicability of this effect in LQT1, nor provide
sufficient data on a possible similar relation in LQT2. It
should be emphasized that the association between
D85N and QT interval in type 1 LQTS should be repli-
cated in another material. However, we realize that this is
not an easy task considering the population prevalence of
D85N. Thus, any replication material should contain
hundreds of genetically uniform patients with type 1
LQTS.
Our study also provides evidence that the KCNE1
D85N variant may be associated with a more severe
phenotype of type 1 LQTS, as the proportions of
480
460
440
420
400
D85D major
homozygotes
D85N
heterozygotes
N85N minor
homozygotes
Males
QT
c
(ms)
A
KCNE1 D85N genotype
500
480
460
440
420
400
D85D major
homozygotes
D85N
heterozygotes
N85N minor
homozygotes
Females
QT
c
(ms)
B
KCNE1 D85N genotype
500
520 520
n=2 0 5 n=6 n=2 n=2 6 9 n=1 0 n=0
p = 0.003 p = 0.935
Figure 1 QTc-interval duration in different KCNE1 D85N genotype classes in males and females with KCNQ1 G589D. Box plots show
medians and interquartile ranges. The p values in linear regression analyses using additive genotypic model are shown for (A) males and
(B) females separately. For interaction between D85N genotype and sex, p = 0.028. QTc, heart rate-corrected QT-interval.
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nificantly higher in D85N heterozygotes than in non-
carriers (Figure 2). Indirectly, these associations suggest
that D85N carriers may seek medical help more often
than non-carriers. A similar but non-significant trend
was detected in the occurrence of syncope and use of
pacemaker or implantable cardioverter-defibrillator. Pau-
lussen et al. [15] identified 2 carriers of the N85 allele
among 32 patients with drug-induced LQTS, while no
such carriers were observed in the series of 34 patients
with torsades de pointes studied by Mank-Seymour et al.
[28]. Sotoodehnia et al. [29] suggested that D85N could
be associated with a higher death rate in males but not
in females. Clearly, more extensive population-based
studies are required in which the role KCNE1 D85N
variation as determinant of life-threatening and fatal
arrhythmias will be explored. Polymorphisms in another
gene, NOS1AP, have also been associated with QT pro-
longation and cardiac events in LQTS patients [30].
Conclusions
Our study suggests that KCNE1 D85N variation has a
gender-dependent QT-prolonging effect in KCNQ1
G589D mutation carriers and could thus complicate the
symptoms of LQTS. Previously, this variant has not
been studied in vivo in a large cohort of LQTS mutation
carriers. As KCNE1 D85N is relatively frequent occur-
ring in 2-3% of the general population, this interaction
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Figure 2 Association of the KCNE1 D85N variant with selected clinical variables in KCNQ1 G589D carriers. Percentage of (A) probands,
(B) patients having experienced syncope, (C) patients with beta blocker medication, and (D) patients with pacemaker or ICD, in different KCNE1
D85N genotype classes. The p value between D85N heterozygotes and D85D major homozygotes in Fisher exact test is shown above the
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direct implications in counseling of LQTS patients.
However, future studies are required to assess the direct
risks of arrhythmias and/or sudden death in LQTS
patients carrying KCNE1 N85.
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